Sophie Rivière

Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

Sophie Dupuis‐Girod, Isabelle Ginon, Jean‐Christophe Saurin et al. · JAMA · 2012 · 384 citations

Medicine, Cardiology, Pharmacotherapy +13

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Pierre Charles, Benjamin Terrier, Élodie Perrodeau et al. · Annals of the Rheumatic Diseases · 2018 · 336 citations

Life Sciences, Immunology, Pharmacotherapy +15

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

Hélène Vallet, Sophie Rivière, Alice Sanna et al. · Journal of Autoimmunity · 2015 · 216 citations · Full text

Life Sciences, Immunology, Internal Medicine +12

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

Hélène Vallet, P. Sève, Lucie Biard et al. · Arthritis & Rheumatology · 2016 · 175 citations

Pharmacy, Immunology, Pharmacotherapy +16

Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross‐over controlled trial in a rare disease

Ségolène Gaillard, Sophie Dupuis‐Girod, Florent Boutitie et al. · Journal of Thrombosis and Haemostasis · 2014 · 122 citations

Medicine, Pharmacology, Pharmacotherapy +15